Data as of .
ARKG vs IDNA: which is really different?
ARKG and IDNA hold 10% of their weight in the same names, and ARKG returned more over the year.
ETFIQ Off-Index Score: IDNA scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
10% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, ARKG and IDNA hold 10% of their money in the same securities at the same weight.
| Holding | ARKG | IDNA |
|---|---|---|
| TWIST BIOSCIENCE CORP | 9.63% | 7.09% |
| CRISPR THERAPEUTICS AG | 5.63% | 1.50% |
| PERSONALIS INC | 5.16% | 0.94% |
| INTELLIA THERAPEUTICS INC | 1.49% | 0.47% |
| PACIFIC BIOSCIENCES OF CALIF | 0.70% | 0.36% |
| PRIME MEDICINE INC | 1.12% | 0.09% |
| Only in ARKG | Only in IDNA |
|---|---|
| 10X GENOMICS INC-CLASS A 9.39% | MODERNA 9.54% |
| TEMPUS AI INC-CL A 8.92% | GENMAB 4.13% |
| GUARDANT HEALTH INC 4.87% | BAYER AG 3.87% |
| ABSCI CORP 4.76% | REVOLUTION MEDICINES 3.76% |
| NATERA INC 4.25% | IOVANCE BIOTHERAPEUTICS INC 3.67% |
| ILLUMINA INC 4.13% | REGENERON PHARMACEUTICALS 3.63% |
| CAREDX INC 3.78% | TAKEDA PHARMACEUTICAL 3.62% |
| ELI LILLY & CO 3.51% | INCYTE CORP 3.60% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 18, 2026 and Sep 21, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| ARKG | IDNA | ARKG | IDNA | ARKG | IDNA | |
| 3 months | +40.1% | +30.3% | +37.9 pts | +28.1 pts | +42.6 pts | +32.8 pts |
| 6 months | +98.2% | +41.4% | +80.2 pts | +23.4 pts | +74.0 pts | +17.2 pts |
| 1 year | +87.1% | +73.4% | +70.6 pts | +56.9 pts | +65.4 pts | +51.7 pts |
| 3 years | +74.8% | +91.3% | −3.6 pts | +12.9 pts | −23.4 pts | −6.9 pts |
| Since launch | +174.6% | +69.7% | −186.8 pts | −123.9 pts | −504.0 pts | −242.0 pts |
| ARKG ARK Genomic Revolution ETF Holds 33 stocks in genomics and gene editing, 4% of its weight in S&P 500 companies | IDNA iShares Genomics Immunology and Healthcare ETF Holds 62 stocks in genomics and gene editing, 24% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | ARK | iShares |
| Theme | Genomics and gene editing | Genomics and gene editing |
| In the S&P 500 | 3.5% | 23.9% |
| Active share vs the S&P 500 | 98.5% | 99.1% |
| In the Nasdaq-100 | 0.0% | 7.0% |
| Holdings | 33 | 62 |
| Top ten, share of the fund | 60.4% | 46.2% |
| Expense ratio | 0.75% | 0.47% |
| Fee for the differing part | 0.76% | 0.47% |
| Total return, 1 year | +87.1% | +73.4% |
| vs the S&P 500 | +70.6 pts | +56.9 pts |
| vs the Nasdaq-100 | +65.4 pts | +51.7 pts |
| Below its high | −53.8% | −24.7% |
| Net assets | $2.2bn | $271m |
ARKG in plain words
By weight, 4% of ARKG's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 60% of the fund across 33 positions, as published by its issuer for Sep 21, 2026. Over the year to Sep 18, 2026 the fund returned +87.1% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 70.6 pts. It sits 53.8% below its all-time high of Jan 20, 2021.
IDNA in plain words
By weight, 24% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 46% of the fund across 62 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +73.4% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 56.9 pts. It sits 24.7% below its all-time high of Sep 2, 2021.
Questions people ask
- Do ARKG and IDNA hold the same stocks?
- By their latest filings, 10% of their books are the same securities at the same weight, which is mostly different names. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, ARKG or IDNA?
- ARKG has 4% of its weight in S&P 500 names and IDNA has 24%, so IDNA differs more from the index.
- Which is cheaper, ARKG or IDNA?
- ARKG charges 0.75% a year and IDNA charges 0.47%, so IDNA is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, ARKG against IDNA, data as of Sep 18, 2026. https://etfiq.com/compare/themes/arkg-vs-idna Free to use with attribution; the underlying files are at Open data.